444 related articles for article (PubMed ID: 28042497)
1. Regulation and role of post-translational modifications of enhancer of zeste homologue 2 in cancer development.
Lu H; Li G; Zhou C; Jin W; Qian X; Wang Z; Pan H; Jin H; Wang X
Am J Cancer Res; 2016; 6(12):2737-2754. PubMed ID: 28042497
[TBL] [Abstract][Full Text] [Related]
2. Post-translational modifications of EZH2 in cancer.
Li Z; Li M; Wang D; Hou P; Chen X; Chu S; Chai D; Zheng J; Bai J
Cell Biosci; 2020 Dec; 10(1):143. PubMed ID: 33308321
[TBL] [Abstract][Full Text] [Related]
3. Regulation and Role of EZH2 in Cancer.
Yamaguchi H; Hung MC
Cancer Res Treat; 2014 Jul; 46(3):209-22. PubMed ID: 25038756
[TBL] [Abstract][Full Text] [Related]
4. The noncanonical role of EZH2 in cancer.
Huang J; Gou H; Yao J; Yi K; Jin Z; Matsuoka M; Zhao T
Cancer Sci; 2021 Apr; 112(4):1376-1382. PubMed ID: 33615636
[TBL] [Abstract][Full Text] [Related]
5. Epigenetic regulation of cancer progression by EZH2: from biological insights to therapeutic potential.
Gan L; Yang Y; Li Q; Feng Y; Liu T; Guo W
Biomark Res; 2018; 6():10. PubMed ID: 29556394
[TBL] [Abstract][Full Text] [Related]
6. Going beyond Polycomb: EZH2 functions in prostate cancer.
Park SH; Fong KW; Mong E; Martin MC; Schiltz GE; Yu J
Oncogene; 2021 Sep; 40(39):5788-5798. PubMed ID: 34349243
[TBL] [Abstract][Full Text] [Related]
7. PCAF-primed EZH2 acetylation regulates its stability and promotes lung adenocarcinoma progression.
Wan J; Zhan J; Li S; Ma J; Xu W; Liu C; Xue X; Xie Y; Fang W; Chin YE; Zhang H
Nucleic Acids Res; 2015 Apr; 43(7):3591-604. PubMed ID: 25800736
[TBL] [Abstract][Full Text] [Related]
8. Regulation of T Cell Differentiation and Function by EZH2.
Karantanos T; Chistofides A; Barhdan K; Li L; Boussiotis VA
Front Immunol; 2016; 7():172. PubMed ID: 27199994
[TBL] [Abstract][Full Text] [Related]
9. Noncanonical Functions of the Polycomb Group Protein EZH2 in Breast Cancer.
Anwar T; Gonzalez ME; Kleer CG
Am J Pathol; 2021 May; 191(5):774-783. PubMed ID: 33556366
[TBL] [Abstract][Full Text] [Related]
10. EZH2: not EZHY (easy) to deal.
Deb G; Singh AK; Gupta S
Mol Cancer Res; 2014 May; 12(5):639-53. PubMed ID: 24526064
[TBL] [Abstract][Full Text] [Related]
11. O-GlcNAcylation regulates EZH2 protein stability and function.
Chu CS; Lo PW; Yeh YH; Hsu PH; Peng SH; Teng YC; Kang ML; Wong CH; Juan LJ
Proc Natl Acad Sci U S A; 2014 Jan; 111(4):1355-60. PubMed ID: 24474760
[TBL] [Abstract][Full Text] [Related]
12. Regulation of EZH2 by SMYD2-Mediated Lysine Methylation Is Implicated in Tumorigenesis.
Zeng Y; Qiu R; Yang Y; Gao T; Zheng Y; Huang W; Gao J; Zhang K; Liu R; Wang S; Hou Y; Yu W; Leng S; Feng D; Liu W; Zhang X; Wang Y
Cell Rep; 2019 Nov; 29(6):1482-1498.e4. PubMed ID: 31693890
[TBL] [Abstract][Full Text] [Related]
13. High histone acetylation and decreased polycomb repressive complex 2 member levels regulate gene specific transcriptional changes during early embryonic stem cell differentiation induced by retinoic acid.
Lee ER; Murdoch FE; Fritsch MK
Stem Cells; 2007 Sep; 25(9):2191-9. PubMed ID: 17525233
[TBL] [Abstract][Full Text] [Related]
14. No Easy Way Out for EZH2: Its Pleiotropic, Noncanonical Effects on Gene Regulation and Cellular Function.
Wang J; Wang GG
Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33327550
[TBL] [Abstract][Full Text] [Related]
15. Astemizole arrests the proliferation of cancer cells by disrupting the EZH2-EED interaction of polycomb repressive complex 2.
Kong X; Chen L; Jiao L; Jiang X; Lian F; Lu J; Zhu K; Du D; Liu J; Ding H; Zhang N; Shen J; Zheng M; Chen K; Liu X; Jiang H; Luo C
J Med Chem; 2014 Nov; 57(22):9512-21. PubMed ID: 25369470
[TBL] [Abstract][Full Text] [Related]
16. Epigenetic regulation of cancer biology and anti-tumor immunity by EZH2.
Christofides A; Karantanos T; Bardhan K; Boussiotis VA
Oncotarget; 2016 Dec; 7(51):85624-85640. PubMed ID: 27793053
[TBL] [Abstract][Full Text] [Related]
17. Emerging Roles of LncRNAs in the EZH2-regulated Oncogenic Network.
Hao A; Wang Y; Stovall DB; Wang Y; Sui G
Int J Biol Sci; 2021; 17(13):3268-3280. PubMed ID: 34512145
[TBL] [Abstract][Full Text] [Related]
18. Polycomb Directed Cell Fate Decisions in Development and Cancer.
German B; Ellis L
Epigenomes; 2022 Sep; 6(3):. PubMed ID: 36135315
[TBL] [Abstract][Full Text] [Related]
19. Targeting Enhancer of Zeste Homolog 2 as a promising strategy for cancer treatment.
Marchesi I; Bagella L
World J Clin Oncol; 2016 Apr; 7(2):135-48. PubMed ID: 27081636
[TBL] [Abstract][Full Text] [Related]
20. Structure-Activity Relationship Studies for Enhancer of Zeste Homologue 2 (EZH2) and Enhancer of Zeste Homologue 1 (EZH1) Inhibitors.
Yang X; Li F; Konze KD; Meslamani J; Ma A; Brown PJ; Zhou MM; Arrowsmith CH; Kaniskan HÜ; Vedadi M; Jin J
J Med Chem; 2016 Aug; 59(16):7617-33. PubMed ID: 27468126
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
